BioSpace News Archive

Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, today announced a Series B funding of $225 million.

Velodyne Lidar, Inc. (NASDAQ: VLDR, VLDRW), today announced that it will release its second quarter 2022 financial results for the period ended June 30, 2022, on Monday, August 8, 2022, after the market close.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced a two-year sponsored research agreement with Sunnybrook Research Institute (SRI) to expedite the identification of novel drug candidates that inhibit Bax and Bak with high potency, specificity and appropriate pharmacokinetic properties for the development as therapeutics for neurodegenerative diseases, specifically in amyotrophic lateral sclerosis (ALS).

Exactech Launches Significant Update to Equinoxe ® Shoulder Preoperative Planning App.

n-Lorem, a nonprofit foundation, today announced the publication of an invited perspective article authored by n-Lorem founder and CEO, Dr. Stanley Crooke, and titled “Establishing an Environment in Which Rigorous Scientific Inquiry is Practiced”.

BlackRock and QLS Advisors LLC, a life sciences technology and advisory firm, have announced a partnership through BlackRock Systematic to develop data-driven investment solutions to help accelerate biomedical innovation.

GRAIL, LLC announced today that the NHS-Galleri trial successfully completed enrollment in just over 10 months.

Therapeutic Solutions International announced today granting of Emergency IND # 28685 and a “May Proceed Notification” from the Food and Drug Administration (FDA) for the treatment of advanced COVID-19 ARDS outside of the currently ongoing Double Blind Placebo Controlled Phase III clinical trial.

Adial Pharmaceuticals, Inc. today announced that it plans to report topline results from the Company’s ONWARD™ Phase 3 clinical trial on Wednesday, July 20, 2022.

July 18, 2022 13:20 UTC Johnson & Johnson’s Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022.